Merck & Co.‘s planned debut this fall of an injectable form of its breakthrough cancer treatment Keytruda will simplify care, ...

Amazon was struggling before mixed second-quarter results, but it has several attractive growth opportunities. Mounting ...

Takeda has shot down candidates acquired in its $525 million Maverick Therapeutics takeover, blowing a hole in its oncology R ...

We recently published a list of The Best and Worst Dow Stocks. In this article, we are going to take a look at where Merck & ...

We can contribute innovation globally,” Xia says. “I think that's very satisfying.” As director general of the World Health ...

Following announcement of prioritized development strategy for evorpacept in combination with anti-cancer antibodies at R&D Day in March, Company is on track to initiate Phase 2 ASPEN-Breast and Phase ...

In recent months, drugmakers told Reuters they had taken the unusual step of sending more medicines by air to the US. Two of ...

Merck & Co. has become a standout player in the Dow thanks to its steady revenue streams and hedge fund popularity. It ranks ...

Yelena Y. Janjigian, MD, discusses how to manage the potential adverse events of pembrolizumab when using the recently approved combination of pembrolizumab plus trastuzumab and chemotherapy.

Robert F. Kennedy, Jr. discusses the findings of the Centers for Disease Control and Prevention’s latest Autism and Developmental Disabilities Monitoring Network survey, Washington, D.C., U.S ...